On Tuesday, RXi Pharmaceuticals Corp (NASDAQ:RXII)’s shares declined -15.48% to $0.710, as a biotechnology corporation, stated its financial results for the fourth quarter and year ended December 31, 2014, and offered a business update.
The past year has seen a steady growth and evolution for RXi Pharmaceuticals,” said Dr. Geert Cauwenbergh, President and CEO of the Corporation. He added that, “In 2014 we harvested the first results from our first Phase 2a study with RXI-109 that demonstrate that our drug is active in the target population. These results offered us with guidance on treatment regimen and duration for RXI-109 in patients with hypertrophic scars. Add to that our progress in ophthalmology towards a clinical trial for retinal scarring, in addition to the attainment of Samcyprone™, and we feel that we are well positioned to extend our growth curve into the current year; all while focusing on containing cash burn in line with expectations for a biotechnology stage corporation that is in mid-stage development with its first two products.”
RXi Pharmaceuticals Corporation, a biotechnology corporation, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The corporation develops therapies based on siRNA technology and immunotherapy agents.
Aeropostale Inc(NYSE:ARO)’s shares dropped -1.43% to $3.44, during the last trading session on Tuesday, as Aeropostale, have collected and donated 5 million pairs of jeans since their Teen for Jeans initiative launched eight years ago. This year alone, teens and schools nationwide joined forces with the teen retailer and organization to collect over 700,000 pairs of jeans that have already been donated to homeless teens throughout the U.S., Canada, and Mexico.
Over 13,000 schools across the United States, Canada, and Mexico take partd in Teens for Jeans this year, more schools than any year in the campaign’s eight-year history. Corner Canyon High School in Draper, UT collected the most jeans (9,146 pairs) and will be receiving a $5,000 school grant, a concert by British pop band, The Vamps, and Aeropostale shirts.
Aéropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing. The corporation also offers casual clothing and accessories focusing on kids between the ages of 4 to 12 year olds.
At the end of Tuesday’s trade, Opexa Therapeutics Inc (NASDAQ:OPXA)‘s shares dipped -9.89% to $0.428, as Opexa Therapeutics, disclosed that it has accomplished its formerly uncovered rights offering. Opexa raised $13,804,140 in gross proceeds, before expenses, through subscriptions for 25,098,437 units, counting the exercise of over-subscription privileges.
Each unit is composed of one share of ordinary stock and a warrant to purchase one additional share of ordinary stock. Net proceeds, after deduction of fees and expenses, counting dealer-manager fees, are predictable to be about $12 million.
Opexa Therapeutics, Inc., a biopharmaceutical corporation, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology.
Arrowhead Research Corp (NASDAQ:ARWR), ended its Tuesday’s trading session with -7.75% loss, and closed at $7.38, as Arrowhead Research Corporation, declared that the United States Food and Drug Administration (FDA) informed the Corporation that it can proceed with a multiple-dose Phase 2b clinical study of ARC-520, its clinical candidate for the treatment of chronic hepatitis B infection, under an investigational new drug (IND) application formerly filed with the FDA.
The clinical study, titled Heparc-2004, is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 administered intravenously to patients with chronic immune active HBV infection maintained on entecavir or tenofovir therapy. The study is planned to enroll up to 12 patients who will be randomized at a ratio of 2:1 with 8 patients receiving 1 mg/kg of ARC-520 and 4 patients receiving placebo. Each patient will receive 3 total doses, once every 4 weeks. Patients will be followed through Day 147.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The corporation’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
